Key Documents

View All Documentation

305189

Platinum

Name: Platinum
Brand: ALDRICH

foil, thickness 0.5 mm, 99.9% trace metals basis

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

CAS Number:

7440-06-4

Molecular Weight:

195.08

NACRES:

NA.23

PubChem Substance ID:

24858411

UNSPSC Code:

12352300

EC Number:

231-116-1

MDL number:

MFCD00011179

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

Quality Level

100

assay

99.9% trace metals basis

form

foil

resistivity

10.6 μΩ-cm, 20°C

thickness

0.5 mm

bp

3827 °C (lit.)

mp

1772 °C (lit.)

density

21.45 g/cm³ (lit.)

SMILES string

[Pt]

InChI

1S/Pt

InChI key

BASFCYQUMIYNBI-UHFFFAOYSA-N

Description

Preparation Note

7 g = 25 × 25 mm; 14 g = 25 × 50 mm

Storage Class

13 - Non Combustible Solids

wgk

nwg

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

In vivo monitoring the process of tumor growth, metastasis and bacterial infection expressing GFP via real-time optical imaging.

Tao Xiong et al.

Journal of biomedical nanotechnology, 9(2), 274-280 (2013-05-01)

Noninvasive molecular fluorescence imaging in vivo which combines Optical imaging with genetic marker technology can real time monitor the development of tumor, through the use of human adenoid cystic carcinoma cell (ACC-M) and lung carcinoma cells SPC-A1 were thansfected by

Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405).

Hiroaki Akamatsu et al.

Japanese journal of clinical oncology, 43(6), 664-668 (2013-04-16)

Interstitial lung disease associated with gefitinib is a critical adverse reaction. When geftinib was administered to EGFR-unknown patients, the interstitial lung disease incidence rate was approximately 3-4% in Japan, and usually occurs during the first 4 weeks of treatment. However

Downregulation of glutathione transferase π sensitizes lymphoma/leukaemia cells to platinum-based chemotherapy.

Jianli Chen et al.

British journal of haematology, 162(1), 135-137 (2013-04-12)

View All Related Papers